EVAX

2.25010.84%
BR

Birgitte Rono

Chief Scientific Officer & COO

Dr. Birgitte Rono, Ph.D. serves as Chief Scientific Officer at Evaxion A/S (formerly known as Evaxion Biotech A/S) since September 21, 2021 and serves as its Chief Operating Officer since April 2026 and was its Interim Chief Executive Officer since July 2025 until November 24, 2025. She has been with Evaxion since 2017 and joined its Executive Management in 2021. She brings deep scientific and strategic expertise to the role. She served as Senior Director, Immuno-Oncology at Evaxion A/S (formerly known as Evaxion Biotech A/S). She has experience in biopharmaceutical drug discovery, both in academia and industry. Prior to joining Evaxion, she served as a specialist, team leader and project manager at Novo Nordisk A/S, where she led early drug discovery projects, evaluated in-licensing opportunities and supported drug development projects with pre-clinical and biomarker expertise. Dr. Rono holds a Bachelor's Degree in Medicine and a Master's Degree in Human Biology, both from the University of Copenhagen, Denmark. She received her Ph.D in Experimental Oncology and Immunology from the National Institutes of Health, Bethesda, USA and Copenhagen University Hospital, Denmark.

Positions